Key AI GMP-relevant documents where regulators explicitly address AI / ML or the core compliance expectations that govern AI used in manufacturing (computerized systems, validation/assurance, data integrity, lifecycle control) are listed below with relevant links (Last link check: 2026-02-08, note: links to draft documents may stop working after the consultation phase ends).
FDA (US) — AI in pharma manufacturing & quality
• Artificial Intelligence in Drug Manufacturing (Discussion Paper, 2023) — FDA CDER discussion paper focused on AI use in drug manufacturing (not guidance, but important signal of expectations). https://www.fda.gov/ … edia/165743/download - It also includes many other useful links.
• Considerations for the Use of AI to Support Regulatory Decision-Making for Drug and Biological Products (Guidance, Jan 2025) — framework for establishing credibility of AI models used to support decisions about safety/effectiveness/quality (highly relevant if AI supports GMP/quality conclusions in submissions). https://www.fda.gov/ … -drug-and-biological
• Guiding Principles of Good AI Practice in Drug Development (Jan 2026) — FDA + EMA aligned principles; explicitly spans lifecycle including manufacturing. https://www.fda.gov/ … edia/189581/download
• FDA “Artificial Intelligence for Drug Development” hub page (collects the above + related FDA AI resources). https://www.fda.gov/ … nce-drug-development
GMP/quality foundations that apply to AI systems
• Data Integrity and Compliance With Drug CGMP: Q&A (Dec 2018) — the core FDA data integrity expectations that AI systems must meet (ALCOA+, audit trail, controls, governance). https://www.fda.gov/ … uestions-and-answers
• PAT — A Framework for Innovative Pharmaceutical Development, Manufacturing and Quality Assurance (Guidance; PDF) — not “AI”, but foundational for model-based control/monitoring and advanced analytics in manufacturing. https://www.fda.gov/media/71012/download
• Process Validation: General Principles and Practices (Guidance; PDF) — validation lifecycle principles that also govern AI-enabled control/monitoring when it impacts product quality. https://www.fda.gov/ … es-and-Practices.pdf
• Emerging Technology Program (ETP) (CDER) — FDA program supporting innovative manufacturing technologies (relevant pathway when AI is part of novel manufacturing control/automation). https://www.fda.gov/ … chnology-program-etp
• Advanced Manufacturing Technologies (AMT) Designation Program (Guidance, Dec 2025) — program guidance for advanced manufacturing approaches (useful if AI is embedded in AMT strategy). https://www.fda.gov/ … -designation-program
EMA / EU medicines regulators — AI + EU GMP updates
• EMA Reflection paper on the use of AI in the medicinal product lifecycle (final, 9 Sept 2024; PDF) — covers principles across lifecycle and regulatory expectations when AI outputs are used in regulated submissions (incl. manufacturing-related evidence). https://www.ema.euro … uct-lifecycle_en.pdf
• HMA–EMA Multi-annual AI workplan 2023–2028 (PDF) — network strategy for AI in medicines regulation (important “direction of travel”). https://www.ema.euro … teering-group_en.pdf
• EMA/FDA: Guiding principles of good AI practice in drug development (Jan 2026; PDF) — joint high-level principles (explicitly spanning manufacturing). https://aiforpharma. … in-drug-development/
EU GMP (EudraLex Volume 4) — computerised systems + new AI annex (draft)
• EU GMP Annex 11: Computerised Systems (current; PDF) — the core GMP anchor for any AI used as a computerised system in manufacturing/QMS. https://health.ec.eu … x11_01-2011_en_0.pdf
• European Commission consultation on revising Chapter 4 + Annex 11 and introducing New Annex 22 (Artificial Intelligence) — this is the major EU GMP move specifically targeting AI/ML in manufacturing. https://health.ec.eu … s-chapter-4-annex_en
• Draft “Annex 22: Artificial Intelligence” (consultation PDF) — outlines GMP expectations for AI (intended use, acceptance criteria, test data independence, explainability, operation, etc.). https://health.ec.eu … ion_guideline_en.pdf
• Draft update material for Annex 11/Chapter 4 (consultation PDF) — background and change rationale. https://health.ec.eu … ion_guideline_en.pdf
PIC/S (global GMP inspection cooperation)
• PIC/S PI 041-1: Good Practices for Data Management and Integrity in regulated GMP/GDP environments (final; PDF) — widely relied upon by inspectorates; very relevant for AI data pipelines and governance. https://picscheme.org/docview/4234
• PIC/S PI 011-3: Good Practices for Computerised Systems in Regulated “GxP” Environments (PDF) — inspector-oriented expectations for computerised systems (validation, supplier management, control). https://picscheme.org/docview/3444
UK MHRA
• MHRA GxP Data Integrity Guidance and Definitions (Rev. 1, March 2018; PDF) — strong practical expectations for data integrity controls that apply directly to AI toolchains. https://assets.publi … rch_edited_Final.pdf
Health Canada
• Annex 11 (GUI-0050): Computerized Systems — Health Canada adoption of Annex 11 principles for GMP computerized systems (useful for “regulatory convergence” arguments). https://www.canada.c … ystems-gui-0050.html